Catestatin as a Marker of Cardiovascular Diseases

Cardiovascular and Hematological Disorders - Drug Targets · Published 2026-07-03 · DOI 10.2174/011871529x447719260514063200

Authors (4)

Irina V. Gubareva, Ekaterina Yu. Gubareva, Sergey A. Tokarev, Lina Yu. Shvan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Gubareva, I., Gubareva, E., Tokarev, S., et al. (2026). Catestatin as a Marker of Cardiovascular Diseases. Cardiovascular and Hematological Disorders - Drug Targets. https://doi.org/10.2174/011871529x447719260514063200

Related articles

• Targeting Neuropeptide Y: Novel Approaches to the Treatment of Cardiovascular and Haematological Disorders · Cardiovascular and Hematological Disorders - Drug Targets · 2026 · Same journal
• IgG Kappa Multiple Myeloma with Cutaneous Plasmacytoma and Hypereosinophilic Leukocytosis in a Young Patient: A Rare Case Report · Cardiovascular and Hematological Disorders - Drug Targets · 2026 · Same journal
• Medication Adherence and Persistence to PCSK-9 Inhibitors from Marketing Authorization to the End of Direct Hospital Distribution at ASST Bergamo Ovest in Northern Italy: A Retrospective Observational Study · Cardiovascular and Hematological Disorders - Drug Targets · 2026 · Same journal
• Utilization Trends and Outcomes of Alteplase in Acute Cerebral Ischemia among Patients with Hypertension or Diabetes: A Tertiary Care Experience from Southern Punjab · Cardiovascular and Hematological Disorders - Drug Targets · 2025 · Same journal
• Therapeutic Targets for Myocardial Fibrosis: A Comprehensive Review of Current and Emerging Approaches · Cardiovascular and Hematological Disorders - Drug Targets · 2025 · Same journal
• Muvalaplin: A Novel Oral Therapy for Targeted Reduction of Plasma Lipoprotein(a) · Cardiovascular and Hematological Disorders - Drug Targets · 2026 · Same journal
• Therapeutic Trends in Diabetes Management: A Review on Oral Hypoglycemic Agents (OHAs) Utilization in Tertiary Care · Cardiovascular and Hematological Disorders - Drug Targets · 2025 · Same journal
• Updated Review of Current Therapeutic Approaches for the Management of Sickle Cell Disease · Cardiovascular and Hematological Disorders - Drug Targets · 2025 · Same journal
• Lipoprotein(a) Lowering with Pelacarsen (TQJ230) · Cardiovascular and Hematological Disorders - Drug Targets · 2025 · Same journal
• Integrating AI in Cardiovascular Systems: Innovations in Diagnosis, RiskPrediction, and Management · Cardiovascular and Hematological Disorders - Drug Targets · 2026 · Same journal